<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="367bb2bf-beef-4f9a-b045-0c23e9021701"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use PAROXETINE ORAL SUSPENSION safely and effectively. See full prescribing information for PAROXETINE ORAL SUSPENSION.<br/> Â <br/> PAROXETINE oral suspension<br/> Initial U.S. Approval: 1992<br/>
   </title>
   <effectiveTime value="20240916"/>
   <setId root="134e76f0-45cf-47eb-b6e1-cdb3bb522a0a"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="145588013"/>
            <name>ANI Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="080301870" root="1.3.6.1.4.1.519.1"/>
                        <name>Novitium Pharma LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70954-319" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70954-319" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70954-319" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70954-319" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="7bdfeea7-cf04-443a-a0ca-06793010a359"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250313"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70954-319" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Paroxetine<suffix/>
                        </name>
                        <formCode code="C42994" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Paroxetine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X2ELS050D8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PAROXETINE HYDROCHLORIDE HEMIHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="41VRH5220H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PAROXETINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0BZ5A00FQU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLACRILIN POTASSIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A9CO00M9HV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SACCHARIN SODIUM MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="92RU3N3Y1O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHICONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="250" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70954-319-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210903"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA215003" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210903"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73406" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="rcm">
               <id root="b618b3f5-902c-4613-9d4d-4be7bfa9ccd6"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (5.4) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  11/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="a4cf8a75-e700-4645-a3ac-99f2fa2b6e33"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>BOXED WARNING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. Paroxetine is not approved for use in pediatric patients <content styleCode="italics">[see Use in Specific Populations (8.4)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. <content ID="_Hlk65248427">Paroxetine </content>is not approved for use in pediatric patients. (5.1, 8.4)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="52d8a016-65da-415a-abfc-8fd87ff1934a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS &amp; USAGE</title>
               <text>
                  <paragraph>Paroxetine is indicated in adults for the treatment of:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Major depressive disorder (MDD)</item>
                     <item>Obsessive compulsive disorder (OCD)</item>
                     <item>Panic disorder (PD)</item>
                     <item>Social anxiety disorder (SAD)</item>
                     <item>Generalized anxiety disorder (GAD)</item>
                     <item>Posttraumatic stress disorder (PTSD)</item>
                  </list>
               </text>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Paroxetine is a selective serotonin reuptake inhibitor (SSRI) indicated in adults for the treatment of (1):</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Major Depressive Disorder (MDD)</item>
                           <item>Obsessive Compulsive Disorder (OCD)</item>
                           <item>Panic Disorder (PD)</item>
                           <item>Social Anxiety Disorder (SAD)</item>
                           <item>Generalized Anxiety Disorder (GAD)</item>
                           <item>Â Posttraumatic Stress Disorder (PTSD)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="a5bacf85-a8dd-4504-a4ee-a3f92f6ab546"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE &amp; ADMINISTRATION</title>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Shake oral suspension well before administration (2.1)</item>
                           <item>Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: (2.2)</item>
                        </list>
                        <table cellspacing="0" cellpadding="0" border="0" width="564.053">
                           <colgroup>
                              <col width="21.4218344730016%"/>
                              <col width="37.2907333176138%"/>
                              <col width="41.2874322093846%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Indication</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Starting Dose</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Maximum Dose</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">MDD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">50 mg<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">OCD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">60 mg<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">PD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">60 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">PTSD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">50 mg<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered" styleCode="disc">
                           <item>Recommended starting dosage for SAD and GAD is 20 mg daily. (2.3)</item>
                           <item>Elderly patients, patients with severe renal impairment or severe hepatic impairment: Starting dosage is 10 mg daily. Maximum dosage is 40 mg daily. (2.4)</item>
                           <item>Â When discontinuing paroxetine, reduce dosage gradually. (2.6, 5.7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="077f9842-f373-435f-89b7-5b986095b9cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 Administration Information</title>
                     <text>
                        <paragraph>Administer paroxetine oral suspension as a single daily dose in the morning, with or without food.</paragraph>
                        <br/>
                        <paragraph>Shake the oral suspension well before administration.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="ae129f0d-0319-4a5b-b925-718ccf1c43cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2 Recommended Dosage for MDD, OCD, PD, and PTSD</title>
                     <text>
                        <paragraph>The recommended starting dosages and maximum dosages of paroxetine oral suspensionÂ in patients with MDD, OCD, PD, and PTSD are presented in Table 1.</paragraph>
                        <br/>
                        <paragraph>In patients with an inadequate response, increase dosage in increments of 10 mg per day at intervals of at least 1 week, depending on tolerability.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 1: Recommended Daily Dosage of Paroxetine Oral SuspensionÂ in Patients with MDD, OCD, PD, and PTSD</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="564.053">
                           <colgroup>
                              <col width="21.4218344730016%"/>
                              <col width="37.2907333176138%"/>
                              <col width="41.2874322093846%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Indication</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Starting Dose</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Maximum Dose</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">MDD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">50 mg<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">OCD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">60 mg<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">PD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">60 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">PTSD<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20 mg<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">50 mg<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="b7b027e9-06f9-4f24-92cf-47df0cca6341"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Recommended Dosage for SAD and GAD</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">SAD</content>
                        </paragraph>
                        <paragraph>The starting and recommended dosage in patients with SAD is 20 mg daily. In clinical trials the effectiveness of paroxetine oral suspensionÂ was demonstrated in patients dosed in a range of 20 mg to 60 mg daily. While the safety of paroxetine oral suspensionÂ has been evaluated in patients with SAD at doses up to 60 mg daily, available information does not suggest any additional benefit for doses above 20 mg daily <content styleCode="italics">[see Clinical Studies (14.4)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">GAD</content>
                        </paragraph>
                        <paragraph>The starting and recommended dosage in patients with GAD is 20 mg daily. In clinical trials the effectiveness of paroxetine oral suspensionÂ in GAD was demonstrated in patients dosed in a range of 20 mg to 50 mg daily. There is not sufficient evidence to suggest a greater benefit to doses higher than 20 mg daily <content styleCode="italics">[see Clinical Studies (14.5)]</content>.</paragraph>
                        <br/>
                        <paragraph>In patients with an inadequate response, increase dosage in increments of 10 mg per day at intervals of at least 1 week, depending on tolerability.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="9cadc268-7713-4ea8-8ff2-3910c9081006"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Screen for Bipolar Disorder Prior to Starting Paroxetine Oral Suspension</title>
                     <text>
                        <paragraph>Prior to initiating treatment with paroxetine oral suspensionÂ or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania <content styleCode="italics">[see Warnings and Precautions (5.6)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="eada80cf-1bdb-4e2a-a63e-800aac97b2b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.5 Recommended Dosage for Elderly Patients, Patients with Severe Renal Impairment, and Patients with Severe Hepatic Impairment</title>
                     <text>
                        <paragraph>The recommended initial dosage is 10 mg per day for elderly patients, patients with severe renal impairment, and patients with severe hepatic impairment. Dosage should not exceed 40 mg/day.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.6">
                     <id root="33a89542-f37d-434c-99ab-01cec69b8f30"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.6 Switching Patients to or From a Monoamine Oxidase Inhibitor (MAOI)</title>
                     <text>
                        <paragraph>At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI and initiation of paroxetine oral suspension. In addition, at least 14 days must elapse after stopping paroxetineÂ oral suspension before starting an MAOI antidepressant <content styleCode="italics">[see Contraindications (4), Warnings and Precautions (5.2)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.7">
                     <id root="3a4de69a-e9db-4453-a13d-c68da06e7986"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.7 Discontinuation of Treatment With Paroxetine Oral Suspension</title>
                     <text>
                        <paragraph>Adverse reactions may occur upon discontinuation of paroxetineÂ oral suspension<content styleCode="italics">[see Warnings and Precautions (5.7)]. </content>Gradually reduce the dosage rather than stopping paroxetine oral suspensionÂ abruptly whenever possible.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="c632b803-ea2d-4a97-b51c-b39f1b94c8d1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS &amp; STRENGTHS</title>
               <text>
                  <paragraph>Paroxetine Oral Suspension is available as:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>10 mg/5 mL orange colored, orange flavored suspension in bottles containing 250 mL.</item>
                  </list>
               </text>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Oral suspension: 10 mg/5 mL. (3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="a490a096-79de-4876-8564-6c47ae969e0b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Paroxetine oral suspensionÂ is contraindicated in patients:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome <content styleCode="italics">[see Warnings and Precautions (5.2), Drug Interactions (</content>7<content styleCode="italics">)].</content>
                     </item>
                     <item>Taking thioridazine because of risk of QT prolongation <content styleCode="italics">
                           <content styleCode="italics">[see Warnings and Precautions (5.3), Drug Interactions (7)].</content>
                        </content>
                     </item>
                     <item>Taking pimozide because of risk of QT prolongation <content styleCode="italics">[see Warnings and Precautions (5.3), Drug Interactions (7)].</content>
                     </item>
                     <item>With known hypersensitivity (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or any of the inactive ingredients in paroxetine oral suspension <content styleCode="italics">[see Adverse Reactions (6.1), (6.2)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of discontinuing a MAOI. (4, 5.3, 7)</item>
                           <item>Concomitant use of pimozide or thioridazine. (4, 5.3,7)</item>
                           <item>Known hypersensitivity to paroxetine or to any of the inactive ingredients in paroxetine oral suspension. (4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="41e6d4ac-05eb-4705-b654-3998839c515f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Serotonin Syndrome: </content>Increased risk when co-administered with other serotonergic agents, but also when taken alone. If occurs, discontinue paroxetine oral suspensionÂ and serotonergic agents and initiate supportive measures. (5.2)<content styleCode="italics">Â </content>
                           </item>
                           <item>
                              <content styleCode="italics">Embryofetal Toxicity</content>: May cause fetal harm. Meta-analyses of epidemiological studies have shown increased risk (less than 2-fold) of cardiovascular malformations with exposure during the first trimester. (5.4, 8.1)Â </item>
                           <item>
                              <content styleCode="italics">Increased Risk of Bleeding</content>: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (5.5)</item>
                           <item>
                              <content styleCode="italics">Activation of Mania/Hypomania</content>: Screen patients for bipolar disorder. (5.6)</item>
                           <item>
                              <content styleCode="italics">Seizures</content>: Use with caution in patients with seizure disorders. (5.8)</item>
                           <item>
                              <content styleCode="italics">Angle-Closure Glaucoma</content>: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. (5.9)</item>
                           <item>Â <content styleCode="italics">Sexual Dysfunction:</content> Paroxetine oral suspensionÂ may cause symptoms of sexual dysfunction. (5.13)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="1d7347f9-ea05-4811-8133-0f03ea47790d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults</title>
                     <text>
                        <paragraph>In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Risk Differences of the Number of Patients with Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="550">
                           <colgroup>
                              <col width="22.7256208358571%"/>
                              <col width="77.2743791641429%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Age Range</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Drug-Placebo Difference in Number of Patients with Suicidal Thoughts and Behaviors per 1,000 Patients Treated</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold">Increases </content>
                                    <content styleCode="bold">Compared </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold"/>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">&lt;18 years old <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14 additional cases<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">18-24 years old <br/>Â <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5 additional cases<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold"> Decreases </content>
                                    <content styleCode="bold">Compared </content>
                                    <content styleCode="bold">to</content>
                                    <content styleCode="bold"/>
                                    <content styleCode="bold"> Placebo</content>
                                    <content styleCode="bold"/>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">25-64 years old <br/>Â <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 fewer case<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">â¥65 years old <br/>Â <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6 fewer cases<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>Paroxetine oral suspensionÂ is not approved for use in pediatric patients.</paragraph>
                        <br/>
                        <paragraph>It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.</paragraph>
                        <br/>
                        <paragraph>Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing paroxetineÂ oral suspensionÂ , in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="57d74588-7198-4499-a8f0-ad3cc48c3e04"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Serotonin Syndrome</title>
                     <text>
                        <paragraph>SSRIs, including paroxetine, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines and St. Johnâs Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs <content styleCode="italics">[see Contraindications (4), Drug Interactions (7.1)]</content>. Serotonin syndrome can also occur when these drugs are used alone.</paragraph>
                        <br/>
                        <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).</paragraph>
                        <br/>
                        <paragraph>The concomitant use of paroxetine oral suspensionÂ with MAOIs is contraindicated. In addition, do not initiate paroxetine oral suspensionÂ in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking paroxetineÂ oral suspensionÂ , discontinue paroxetine oral suspensionÂ before initiating treatment with the MAOI <content styleCode="italics">[see Contraindications (4), Drug Interactions (7)]</content>.</paragraph>
                        <br/>
                        <paragraph>Monitor all patients taking paroxetine oral suspensionÂ for the emergence of serotonin syndrome. Discontinue treatment with paroxetine oral suspensionÂ and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of paroxetine oral suspensionÂ with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="c03f7fb9-9466-4009-98c3-10df5e8d39ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Drug Interactions Leading to QT Prolongation</title>
                     <text>
                        <paragraph>The CYP2D6 inhibitory properties of paroxetine can elevate plasma levels of thioridazine and pimozide. Since thioridazine and pimozide given alone produce prolongation of the QTc interval and increase the risk of serious ventricular arrhythmias, the use of paroxetine is contraindicated in combination with thioridazine and pimozide <content styleCode="italics">[see Contraindications (4), Drug Interactions (7), Clinical Pharmacology (12.3)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="b99006cc-2312-483b-8db2-798541c98899"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Embryofetal Toxicity</title>
                     <text>
                        <paragraph>Based on meta-analyses of epidemiological studies, exposure to paroxetine in the first trimester of pregnancy is associated with a less than 2-fold increase in the rate of cardiovascular malformations among infants. For women who intend to become pregnant or who are in their first trimester of pregnancy, paroxetine oral suspension should be initiated only after consideration of the other available treatment options <content styleCode="italics">[see Use in Specific Populations (8.1)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="30100055-9e46-4843-b015-167b40f06bf7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Increased Risk of Bleeding</title>
                     <text>
                        <paragraph>Drugs that interfere with serotonin reuptake inhibition, including paroxetine, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage <content styleCode="italics">[see Use in Specific Populations (8.1)]</content>. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.</paragraph>
                        <br/>
                        <paragraph>Inform patients about the increased risk of bleeding associated with the concomitant use of paroxetine oral suspensionÂ and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="9189b428-6682-448a-a1b6-cfc43f14399d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.6 Activation of Mania or Hypomania</title>
                     <text>
                        <paragraph>In patients with bipolar disorder, treating a depressive episode with paroxetine oral suspension or another antidepressant may precipitate a mixed/manic episode. During controlled clinical trials of paroxetine oral suspension, hypomania or mania occurred in approximately 1% of paroxetine oral suspension-treated unipolar patients compared to 1.1% of active-control and 0.3% of placebo-treated unipolar patients. Prior to initiating treatment with paroxetine oral suspension, screen patients for any personal or family history of bipolar disorder, mania, or hypomania.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="bd46a2f1-7409-46c7-80e8-847422f913dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.7 Discontinuation Syndrome</title>
                     <text>
                        <paragraph>Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible <content styleCode="italics">[see Dosage and Administration (2.7)].</content>
                        </paragraph>
                        <br/>
                        <paragraph>During clinical trials of GAD and PTSD, gradual decreases in the daily dose by 10 mg/day at weekly intervals followed by 1 week at 20 mg/day was used before treatment was discontinued. The following adverse reactions were reported at an incidence of 2% or greater for paroxetine and were at least twice that reported for placebo: Abnormal dreams, paresthesia, and dizziness. Adverse reactions have been reported upon discontinuation of treatment with paroxetine in pediatric patients. The safety and effectiveness of paroxetine in pediatric patients have not been established <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (5.1), Use in Specific Populations (8.4)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="a6353f8c-9ac0-4bad-9acd-7c714d752394"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.8 Seizures</title>
                     <text>
                        <paragraph>Paroxetine oral suspension has not been systematically evaluated in patients with seizure disorders. Patients with history of seizures were excluded from clinical studies. During clinical studies, seizures occurred in 0.1% of patients treated with paroxetine. Paroxetine should be prescribed with caution in patients with a seizure disorder. Discontinue paroxetine oral suspensionÂ in any patient who develops seizures.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="2e3fdf88-11ce-4b2f-acf6-b80a97dfd7cc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.9 Angle-Closure Glaucoma</title>
                     <text>
                        <paragraph>The pupillary dilation that occurs following use of many antidepressant drugs including paroxetine may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Cases of angle-closure glaucoma associated with use of paroxetine have been reported. Avoid use of antidepressants, including paroxetine oral suspensionÂ in patients with untreated anatomically narrow angles.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="f3c1ef5b-9c16-4f76-bc14-16d419f0f5a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.10 Hyponatremia</title>
                     <text>
                        <paragraph>Hyponatremia may occur as a result of treatment with SSRIs, including paroxetine. Cases with serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).</paragraph>
                        <br/>
                        <paragraph>In patients with symptomatic hyponatremia, discontinue paroxetine oral suspensionÂ and institute appropriate medical intervention. Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs <content styleCode="italics">[see Use in Specific Populations (8.5)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.11">
                     <id root="eb06d79d-d594-4bc3-a2cd-d22e24ac7dc2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.11 Reduction of Efficacy of Tamoxifen</title>
                     <text>
                        <paragraph>Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer relapse/mortality, may be reduced with concomitant use of paroxetine oral suspensionÂ as a result of paroxetineâs irreversible inhibition of CYP2D6 and lower blood levels of tamoxifen <content styleCode="italics">[see Drug Interactions (7)]</content>. One study suggests that the risk may increase with longer duration of coadministration. However, other studies have failed to demonstrate such a risk. When tamoxifen is used for the treatment or prevention of breast cancer, prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.12">
                     <id root="695c53c7-851b-461c-af6d-74363fddb03d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.12 Bone Fracture</title>
                     <text>
                        <paragraph>Epidemiological studies on bone fracture risk during exposure to some antidepressants, including SSRIs, have reported an association between antidepressant treatment and fractures. There are multiple possible causes for this observation and it is unknown to what extent fracture risk is directly attributable to SSRI treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.13">
                     <id root="af782072-30e1-49bd-8377-fa37844244bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.13 Sexual Dysfunction</title>
                     <text>
                        <paragraph>Use of SSRIs, including paroxetine, may cause symptoms of sexual dysfunction <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm. It is important for prescribers to inquire about sexual function prior to initiation of paroxetine oral suspensionÂ and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="ba6fa905-7e8c-4ff2-9f3f-e3a556671cbf"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are included in more detail in other sections of the prescribing information: </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hypersensitivity reactions to paroxetine <content styleCode="italics">[see Contraindications (4)] </content>
                     </item>
                     <item>Suicidal Thoughts and Behaviors <content styleCode="italics">[see Warnings and Precautions (5.1)] </content>
                     </item>
                     <item>Serotonin Syndrome <content styleCode="italics">[see Warnings and Precautions (5.2)] </content>
                     </item>
                     <item>Embryofetal Toxicity <content styleCode="italics">[see Warnings and Precautions (5.4)] </content>
                     </item>
                     <item>Increased Risk of Bleeding <content styleCode="italics">[see Warnings and Precautions (</content>5.5<content styleCode="italics">)] </content>
                     </item>
                     <item>Activation of Mania/Hypomania <content styleCode="italics">[see Warnings and Precautions (5.6)] </content>
                     </item>
                     <item>Discontinuation Syndrome <content styleCode="italics">[see Warnings and Precautions (5.7)] </content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and Precautions (5.8)] </content>
                     </item>
                     <item>Angle-closure Glaucoma <content styleCode="italics">[see Warnings and Precautions (5.9)] </content>
                     </item>
                     <item>Hyponatremia <content styleCode="italics">[see Warnings and Precautions (5.10)] </content>
                     </item>
                     <item>Bone Fracture <content styleCode="italics">[see Warnings and Precautions (5.12)]</content>
                     </item>
                     <item>Â Sexual Dysfunction <content styleCode="italics">[see Warnings and Precautions (5.13)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (â¥5% and at least twice placebo) are abnormal ejaculation, asthenia, constipation, decreased appetite, diarrhea, dizziness, dry mouth, female genital disorder, impotence, infection, insomnia, libido decreased, male genital disorder, nausea, nervousness, somnolence, sweating, tremor, yawn. (6)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Novitium Pharma LLC at 1-855-204-1431 or FDA at 1-800-FDA-1088 or </content>www.fda.gov/medwatch.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="43e928de-c09a-4628-9dd7-d5f2958986f2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <br/>
                        <paragraph>The safety data for paroxetine are from: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>6-week clinical trials in MDD patients who received paroxetine 20 mg to 50 mg once daily</item>
                           <item>12-week clinical trials in OCD patients who received paroxetine 20 mg to 60 mg once daily</item>
                           <item>10- to 12-week clinical trials in PD patients who received paroxetine 10 mg to 60 mg once daily</item>
                           <item>12-week clinical trials in SAD patients who received paroxetine 20 mg to 50 mg once daily</item>
                           <item>8-week clinical trials in GAD patients who received paroxetine 10 mg to 50 mg once daily</item>
                           <item>12-week clinical trials in PTSD patients who received paroxetine 20 mg to 50 mg once daily</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Discontinuation</content>
                        </paragraph>
                        <paragraph>Twenty percent (1,199/6,145) of patients treated with paroxetine in clinical trials in MDD and 16.1% (84/522), 11.8% (64/542), 9.4% (44/469), 10.7% (79/735), and 11.7% (79/676) of patients treated with paroxetine in clinical trials in SAD, OCD, PD, GAD, and PTSD, respectively, discontinued treatment due to an adverse reaction. The most common adverse reactions (<content styleCode="underline">&gt;</content>1%) associated with discontinuation (i.e., those adverse reactions associated with dropout at a rate approximately twice or greater for paroxetine compared to placebo) are presented in Table 3:</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 3: Adverse Reactions Reported as Leading to Discontinuation (â¥1% of Paroxetine -Treated Patients and Greater than Placebo) in MDD, OCD, PD, SAD, GAD, and PTSD Trials</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM1"/>
                        </paragraph>
                        <paragraph>Where numbers are not provided the incidence of the adverse reactions in patients treated with paroxetine was not &gt;1% or was not greater than or equal to 2 times the incidence of placebo.</paragraph>
                        <paragraph>a. Incidence corrected for gender.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Most Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>The most commonly observed adverse reactions associated with the use of paroxetine (incidence of 5% or greater and at least twice that for placebo) were:</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">MDD: </content>Asthenia, sweating, nausea, decreased appetite, somnolence, dizziness, insomnia, tremor, nervousness, ejaculatory disturbance, and other male genital disorders.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">OCD</content>: Nausea, dry mouth, decreased appetite, constipation, dizziness, somnolence, tremor, sweating, impotence, and abnormal ejaculation.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">PD: </content>Asthenia, sweating, decreased appetite, libido decreased, tremor, abnormal ejaculation, female genital disorders, and impotence.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">SAD: </content>Sweating, nausea, dry mouth, constipation, decreased appetite, somnolence, tremor, libido decreased, yawn, abnormal ejaculation, female genital disorders, and impotence.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">GAD: </content>Asthenia, infection, constipation, decreased appetite, dry mouth, nausea, libido decreased, somnolence, tremor, sweating, and abnormal ejaculation.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">PTSD: </content>Asthenia, sweating, nausea, dry mouth, diarrhea, decreased appetite, somnolence, libido decreased, abnormal ejaculation, female genital disorders, and impotence.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions in Patients with MDD</content>
                        </paragraph>
                        <paragraph>Table 4 presents the adverse reactions that occurred at an incidence of 1% or more and greater than placebo in clinical trials of paroxetine-treated patients with MDD.</paragraph>
                        <br/>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 4: Adverse Reactions (â¥1% of Paroxetine-Treated Patients and Greater than Placebo) in 6-Week Clinical Trials for MDD<br/>
                              <renderMultiMedia referencedObject="MM2"/>
                              <br/>
                           </content>a. Includes mostly âlump in throatâ and âtightness in throat.â <br/> b. Percentage corrected for gender. <br/> c. Mostly âejaculatory delay.â <br/> d. Includes âanorgasmia,â âerectile difficulties,â âdelayed ejaculation/orgasm,â and âsexual dysfunction,â and âimpotence.â <br/> e. Includes mostly âdifficulty with micturitionâ and âurinary hesitancy.â <br/> f. Includes mostly âanorgasmiaâ and âdifficulty reaching climax/orgasm.â <br/>
                           <br/> Adverse Reactions in Patients with OCD, PD, and SAD <br/> Table 5 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials in patients with OCD, PD, and SAD<br/>
                           <br/>
                           <content styleCode="bold">Table 5. Adverse Reactions (â¥2% of Paroxetine</content>
                           <content styleCode="bold">-Treated Patients and Greater than Placebo) in 10 to 12-Week Clinical Trials for OCD, PD, and SAD<br/>
                              <renderMultiMedia referencedObject="MM3"/>
                              <br/>
                              <renderMultiMedia referencedObject="MM4"/>
                           </content>Â </paragraph>
                        <br/>
                        <paragraph>a. Percentage corrected for gender.<br/>
                           <content styleCode="underline">Adverse Reactions in Patients with GAD and PTSD<br/>
                           </content>Table 6 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials in patients with GAD and PTSD.<br/>
                           <content styleCode="bold">Table 6.Adverse Reactions (â¥2% of Paroxetine-Treated Patients and Greater than Placebo) in 8- to 12-Week Clinical Trials for GAD and PTSD<sup>a</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <renderMultiMedia referencedObject="MM5"/>
                        <paragraph> Â a.Â Â Â Â Â Â  Percentage corrected for gender.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Dose Dependent Adverse Reactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">MDD</content>Â </paragraph>
                        <paragraph>A comparison of adverse reaction rates in a fixed-dose study comparing paroxetine 10 mg, 20 mg, 30 mg, and 40 mg once daily with placebo in the treatment of MDD revealed dose dependent adverse reactions, as shown in Table 7:Â </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 7. Adverse Reactions (â¥5% of Paroxetine-Treated Patients and â¥ Twice the Rate of Placebo) in a Dose-Comparison Trial in the Treatment of MDD<br/>
                              <renderMultiMedia referencedObject="MM6"/>
                              <br/>
                           </content>
                           <content styleCode="italics">OCD </content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 20 mg, 40 mg, and 60 mg in the treatment of OCD, there was no clear relationship between adverse reactions and the dose of paroxetine to which patients were assigned.</paragraph>
                        <paragraph>
                           <content styleCode="italics"> PD</content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 10 mg, 20 mg, and 40 mg in the treatment of PD, the following adverse reactions were shown to be dose-dependent: asthenia, dry mouth, anxiety, libido decreased, tremor, and abnormal ejaculation.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">SAD </content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 20 mg, 40 mg and 60 mg in the treatment of SAD, for most of the adverse reactions, there was no clear relationship between adverse reactions and the dose of paroxetine to which patients were assigned.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">GAD </content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 20 mg and 40 mg in the treatment of GAD, the following adverse reactions were shown to be dose-dependent: asthenia, constipation, and abnormal ejaculation.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">PTSD </content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 20 mg and 40 mg in the treatment of PTSD, the following adverse reactions were shown to be dose-dependent: impotence and abnormal ejaculation.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Male and Female Sexual Dysfunction</content>
                        </paragraph>
                        <paragraph>Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of SSRI treatment. However, reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and healthcare providers may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in labeling may underestimate their actual incidence.</paragraph>
                        <br/>
                        <br/>
                        <br/>
                        <paragraph>The percentage of patients reporting symptoms of sexual dysfunction in males and females with MDD, OCD, PD, SAD, GAD, and PTSD are displayed in Table 8. </paragraph>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 8. Adverse Reactions Related to Sexual Dysfunction in Patients Treated with <content ID="_Hlk65655833">Paroxetine </content>in Clinical Trials of MDD, OCD, PD, SAD, GAD, and PTSD</content>
                        </paragraph>
                        <br/>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="550">
                           <colgroup>
                              <col width="41.6212286441294%"/>
                              <col width="31.5642796558827%"/>
                              <col width="26.8144916999879%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <br/>Â </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold"> Paroxetine</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold">Placebo</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold">n (males)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold">1446 </content>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold">1042 </content>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <br/>Â Decreased Libido<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 6 to 15<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 0 to 5<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <br/>Â Ejaculatory Disturbance<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 13 to 28<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 0 to 2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <br/>Â Impotence<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 2 to 9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 0 to 3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold">n (females)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold">1822 </content>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â <content styleCode="bold">1340 </content>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <br/>Â Decreased Libido<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 0 to 9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 0 to 2<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <br/>Â Orgasmic Disturbance<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 2 to 9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <br/>Â 0 to 1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Paroxetine treatment has been associated with several cases of priapism. In those cases with a known outcome, patients recovered without sequelae.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hallucinations</content>
                        </paragraph>
                        <paragraph>In pooled clinical trials of paroxetine, hallucinations were observed in 0.2% of paroxetine-treated patients compared to 0.1% of patients receiving placebo.Â </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Less Common Adverse Reactions</content>Â </paragraph>
                        <paragraph>The following adverse reactions occurred during the clinical studies of paroxetine and are not included elsewhere in the labeling.<br/>Â </paragraph>
                        <paragraph>Adverse reactions are categorized by body system and listed in order of decreasing frequency according to the following definitions: Frequent adverse reactions are those occurring on 1 or more occasions in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients; rare adverse reactions are those occurring in fewer than 1/1,000 patients.<br/>Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole</content>Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infrequent</content>: Allergic reaction, chills, face edema, malaise, neck pain; <content styleCode="italics">rare: </content>Adrenergic syndrome, cellulitis, moniliasis, neck rigidity, pelvic pain, peritonitis, sepsis, ulcer.<br/>Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular System Frequent: </content>Hypertension, tachycardia; <content styleCode="italics">infrequent: </content>Bradycardia, hematoma, hypotension, migraine, postural hypotension, syncope; <content styleCode="italics">rare: </content>Angina pectoris, arrhythmia nodal, atrial fibrillation, bundle branch block, cerebral ischemia, cerebrovascular accident, congestive heart failure, heart block, low cardiac output, myocardial infarct, myocardial ischemia, pallor,phlebitis, pulmonary embolus, supraventricular extrasystoles, thrombophlebitis, thrombosis, varicose vein, vascular headache, ventricular extrasystoles.<br/>Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive System<br/>
                           </content>
                           <content styleCode="italics">Infrequent: </content>Bruxism, colitis, dysphagia, eructation, gastritis, gastroenteritis, gingivitis, glossitis, increased salivation, abnormal liver function tests, rectal hemorrhage, ulcerative stomatitis; <content styleCode="italics">rare: </content>Aphthous stomatitis, bloody diarrhea, bulimia, cardiospasm, cholelithiasis, duodenitis, enteritis, esophagitis, fecal impactions, fecal incontinence, gum hemorrhage, hematemesis, hepatitis, ileitis, ileus, intestinal obstruction, jaundice, melena, mouth ulceration, peptic ulcer, salivary gland enlargement, sialadenitis, stomach ulcer, stomatitis, tongue discoloration, tongue edema, tooth caries.<br/>
                           <br/>
                           <content styleCode="italics">Endocrine System<br/>
                           </content>
                           <content styleCode="italics">Rare: </content>Diabetes mellitus, goiter, hyperthyroidism, hypothyroidism, thyroiditis.<br/>
                           <content styleCode="italics">
                              <br/> Hemic and Lymphatic Systems</content>Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infrequent: </content>Anemia, leukopenia, lymphadenopathy, purpura; <content styleCode="italics">rare: </content>Abnormal erythrocytes, basophilia, bleeding time increased, eosinophilia, hypochromic anemia, iron deficiency anemia, leukocytosis, lymphedema, abnormal lymphocytes, lymphocytosis, microcytic anemia, monocytosis, normocytic anemia, thrombocythemia, thrombocytopenia.<br/>
                           <content styleCode="italics">
                              <br/> Metabolic and Nutritional<br/>
                           </content>
                           <content styleCode="italics">Frequent: </content>Weight gain; infrequent: Edema, peripheral edema, SGOT increased, SGPT increased, thirst, weight loss; rare: Alkaline phosphatase increased, bilirubinemia, BUN increased, creatinine phosphokinase increased, dehydration, gamma globulins increased, gout, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hyperphosphatemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, ketosis, lactic dehydrogenase increased, non-protein nitrogen (NPN) increased.<br/>
                           <content styleCode="italics">
                              <br/> Musculoskeletal System<br/>
                           </content>
                           <content styleCode="italics">Frequent: </content>Arthralgia; <content styleCode="italics">infrequent: </content>Arthritis, arthrosis; <content styleCode="italics">rare: </content>Bursitis, myositis, osteoporosis, generalized spasm, tenosynovitis, tetany.<br/>
                           <content styleCode="italics">
                              <br/> Nervous System<br/>
                           </content>
                           <content styleCode="italics">Frequent: </content>Emotional lability, vertigo; <content styleCode="italics">infrequent: </content>Abnormal thinking, alcohol abuse, ataxia, dystonia, dyskinesia, euphoria, hostility, hypertonia, hypesthesia, hypokinesia, incoordination, lack of emotion, libido increased, manic reaction, neurosis, paralysis, paranoid reaction; <content styleCode="italics">rare: </content>Abnormal gait, akinesia, antisocial reaction, aphasia, choreoathetosis, circumoral paresthesias, convulsion, delirium, delusions, diplopia, drug dependence, dysarthria, extrapyramidal syndrome, fasciculations, grand mal convulsion, hyperalgesia, hysteria, manic-depressivereaction, meningitis, myelitis, neuralgia, neuropathy, nystagmus, peripheral neuritis, psychotic depression, psychosis, reflexes decreased, reflexes increased, stupor, torticollis, trismus, withdrawal syndrome.<br/>
                           <content styleCode="italics">
                              <br/> Respiratory System<br/>
                           </content>
                           <content styleCode="italics">Infrequent: </content>Asthma, bronchitis, dyspnea, epistaxis, hyperventilation, pneumonia, respiratory flu; <content styleCode="italics">rare: </content>Emphysema, hemoptysis, hiccups, lung fibrosis, pulmonary edema, sputum increased, stridor, voice alteration.<br/>
                           <content styleCode="italics">
                              <br/> Skin and Appendages<br/>
                           </content>
                           <content styleCode="italics">Frequent: </content>Pruritus; <content styleCode="italics">infrequent: </content>Acne, alopecia, contact dermatitis, dry skin, ecchymosis, eczema, herpes simplex, photosensitivity, urticaria; <content styleCode="italics">rare: </content>Angioedema, erythema nodosum, erythema multiforme, exfoliative dermatitis, fungal dermatitis, furunculosis; herpes zoster, hirsutism, maculopapular rash, seborrhea, skin discoloration, skin hypertrophy, skin ulcer, sweating decreased, vesiculobullous rash.<br/>
                           <content styleCode="italics">
                              <br/> Special Senses</content>Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Frequent</content>: Tinnitus; <content styleCode="italics">infrequent: </content>Abnormality of accommodation, conjunctivitis, ear pain, eye pain, keratoconjunctivitis, mydriasis, otitis media; <content styleCode="italics">rare: </content>Amblyopia, anisocoria, blepharitis, cataract, conjunctival edema, corneal ulcer, deafness, exophthalmos, eye hemorrhage, glaucoma, hyperacusis, night blindness, otitis externa, parosmia, photophobia, ptosis, retinal hemorrhage, taste loss, visual field defect.<br/>
                           <content styleCode="italics">
                              <br/> Urogenital System<br/>
                           </content>
                           <content styleCode="italics">Infrequent: </content>Amenorrhea, breast pain, cystitis, dysuria, hematuria, menorrhagia, nocturia, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, vaginitis; <content styleCode="italics">rare: </content>Abortion, breast atrophy, breast enlargement, endometrial disorder, epididymitis, female lactation, fibrocystic breast, kidney calculus, kidney pain, leukorrhea, mastitis, metrorrhagia, nephritis, oliguria, salpingitis, urethritis, urinary casts, uterine spasm, urolith, vaginal hemorrhage, vaginal moniliasis.</paragraph>
                        <br/>
                        <br/>
                     </text>
                     <effectiveTime value="20250313"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>table-1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="table-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM2">
                           <text>table-2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="table-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>table-3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="table-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM4">
                           <text>table-3-2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="table-3-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM5">
                           <text>spl-table</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="spl-table.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM6">
                           <text>table-5</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="table-5.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="67d2d098-3ed3-4367-b1f8-4ff83c69dff6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following reactions have been identified during post approval use of paroxetine. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <br/>
                        <paragraph>Acute pancreatitis, elevated liver function tests (the most severe cases were deaths due to liver necrosis, and grossly elevated transaminases associated with severe liver dysfunction), Guillain-BarrÃ© syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), syndrome of inappropriate ADH secretion, prolactinemia and galactorrhea; extrapyramidal symptoms whichÂ have included akathisia, bradykinesia, cogwheel rigidity, oculogyric crisis which has been associated with concomitant use of pimozide; status epilepticus, acute renal failure, pulmonary hypertension, allergic alveolitis, anosmia, hyposmia, anaphylaxis, eclampsia, laryngismus, optic neuritis, porphyria, restless legs syndrome (RLS), ventricular fibrillation, ventricular tachycardia (including torsade de pointes), hemolytic anemia, events related to impaired hematopoiesis (including aplastic anemia, pancytopenia, bone marrow aplasia, and agranulocytosis), vasculitic syndromes (such as Henoch-SchÃ¶nlein purpura), and premature births in pregnant women. There has been a case report of severe hypotension when paroxetine was added to chronic metoprolol treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="54e335ee-a102-4f79-92b6-55f276f34932"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 9 presents clinically significant drug interactions with paroxetine.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Table 9: Clinically Significant Drug Interactions with Paroxetine</content>
                  </paragraph>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="624">
                     <colgroup>
                        <col width="22.7340743907653%"/>
                        <col width="77.2659256092347%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">The concomitant use of SSRIs, including paroxetine, and MAOIs increases the risk of serotonin syndrome.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Paroxetine is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue <content styleCode="italics">[see Dosage and Administration (2.5), Contraindications (4), Warnings and Precautions </content>
                              <content styleCode="italics">(5.2)]</content>.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Examples</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold">Pimozide and Thioridazine</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Increased plasma concentrations of pimozide and thioridazine, drugs with a narrow therapeutic index, may increase the risk of QTc prolongation and ventricular arrhythmias.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Paroxetine is contraindicated in patients taking pimozide or thioridazine <content styleCode="italics">[see Contraindications (4)].</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold">Other Serotonergic Drugs</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">The concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Monitor patients for signs and symptoms of serotonin syndrome, particularly during treatment initiation and dosage increases. If serotonin syndrome occurs, consider discontinuation of paroxetine and/or concomitant serotonergic drugs <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Examples</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. Johnâs Wort<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold">Drugs that Interfere with Hemostasis (antiplatelet agents and anticoagulants)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                              <content styleCode="italics"/>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Theconcurrentuse of anantiplateletagentoranticoagulant with paroxetine maypotentiate the risk ofbleeding.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics"> Intervention</content>
                              <content styleCode="italics"/>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Informpatientsofthe increasedrisk of bleedingassociated with the concomitantuse ofparoxetine andantiplateletagentsand anticoagulants. For patients takingwarfarin,carefullymonitor the international normalizedratio<content styleCode="italics"> [see</content>
                              <content styleCode="italics">Warningsand Precautions(5.5)]</content>.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Examples</content>
                              <content styleCode="italics"/>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">aspirin, clopidogrel, heparin,warfarin<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold">Drugs </content>
                              <content styleCode="bold">Highly</content>
                              <content styleCode="bold">Bound toPlasmaProtein</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics"> Clinical Impact</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Paroxetine is highlybound to plasma protein. The concomitant useof paroxetine with another drugthat ishighlyboundto plasma protein may increasefreeconcentrationsofparoxetine or othertightly-bound drugs in plasma<content styleCode="italics">.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Monitor foradversereactionsandreducedosageof paroxetine orother protein-bound drugs as warranted.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Examples</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">warfarin<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold">Drugs</content>
                              <content styleCode="bold"/>
                              <content styleCode="bold"> Metabolized </content>
                              <content styleCode="bold">by </content>
                              <content styleCode="bold">CYP2D6</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Paroxetine is a CYP2D6inhibitor <content styleCode="italics">[see Clinical Pharmacology(12.3)].</content>The concomitant use of paroxetine with a CYP2D6substrate may increasetheexposure of the CYP2D6substrate.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Decreasethe dosage of a CYP2D6substrate if neededwith concomitantparoxetine use.Conversely,anincreaseindosageof a CYP2D6substratemay be needed if paroxetine is discontinued.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Examples</content>
                              <content styleCode="italics"/>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">propafenone,flecainide,atomoxetine, desipramine, dextromethorphan,metoprolol,nebivolol,perphenazine,tolterodine,venlafaxine, risperidone. <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold">Tamoxifen</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics"> Clinical Impact</content>
                              <content styleCode="bold"/>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Concomitant use oftamoxifen with paroxetine maylead to reduced plasmaconcentrations ofthe active metabolite (endoxifen)andreducedefficacyoftamoxifen.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Consideruse ofanalternativeantidepressantwithlittle or noCYP2D6 inhibition <content styleCode="italics">[seeWarningsand Precautions(5.11)].</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">
                              <content styleCode="bold"> Fosamprenavir/Ritonavir</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                              <content styleCode="bold"/>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Co-administration of fosamprenavir/ritonavir withparoxetine significantly decreased plasmalevels of paroxetine.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Anydose adjustment should be guidedbyclinicaleffect (tolerabilityandefficacy).<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Drugs Highly Bound to Plasma Protein</content>: Monitor for adverse reactions and reduce dosage of paroxetineÂ oral suspensionÂ  or other protein-bound drugs (e.g., warfarin) as warranted. (7)</item>
                           <item>
                              <content styleCode="italics">Drugs Metabolized by CYP2D6</content>: Reduce dosage of drugs metabolized by CYP2D6 as warranted. (7)</item>
                           <item>
                              <content styleCode="italics">Concomitant use with tamoxifen</content>: Consider use of an alternative antidepressant with little or no CYP2D6 inhibition. (5.11, 7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="9a04a866-a407-49e0-b68c-aeb0da69defa"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Pregnancy:</content> SSRI use, particularly later in pregnancy, may increase the risk for persistent pulmonary hypertension and symptoms of poor adaptation (respiratory distress, temperature instability, feeding difficulty, hypotonia, irritability) in the neonate. (8.1)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="cd661671-f979-40db-9876-2c53359516f9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including paroxetine, during pregnancy. Healthcare providers are encouraged to advise patients to register by calling the National Pregnancy Registry for Antidepressants 1-866- 961-2388 or visiting online at https://womensmentalhealth.org/ clinical-and-research-programs/pregnancyregistry/antidepressants/.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage <content styleCode="italics">[see Warnings and Precautions (5.5) and Clinical Considerations].</content>
                        </paragraph>
                        <br/>
                        <paragraph>Paroxetine is associated with a less than 2-fold increase in cardiovascular malformations when administered to a pregnant woman during the first trimester. While individual epidemiological studies on the association between paroxetine use and cardiac malformations have reported inconsistent findings, some meta-analyses of epidemiological studies have identified an increased risk of cardiovascular malformations <content styleCode="italics">(see Data)</content>. There are risks of persistent pulmonary hypertension of the newborn (PPHN) <content styleCode="italics">(see Data)</content> and/or poor neonatal adaptation with exposure to selective serotonin reuptake inhibitors (SSRIs), including paroxetine during pregnancy. There also are risks associated with untreated depression in pregnancy <content styleCode="italics">(see Clinical Considerations)</content>. For women who intend to become pregnant or who are in their first trimester of pregnancy, paroxetine should be initiated only after consideration of the other available treatment options.</paragraph>
                        <br/>
                        <paragraph>No evidence of treatment related malformations was observed in animal reproduction studies, when paroxetine was administered during the period of organogenesis at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits. These doses are approximately 8 (rat) and less than 2 (rabbit) times the maximum recommended human dose (MRHD â 60 mg) on an mg/m<sup>2</sup> basis. When paroxetine was administered to female rats during the last trimester of gestation and continued through lactation, there was an increase in the number of pup deaths during the first four days of lactation. This effect occurred at a dose of 1 mg/kg/day which is less than the MRHD on an mg/m<sup>2</sup> basis <content styleCode="italics">(See Data)</content>.</paragraph>
                        <br/>
                        <paragraph>The background risks of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryofetal risk</content>
                        </paragraph>
                        <paragraph>Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective, longitudinal study of 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and the postpartum.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Maternal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Use of paroxetine in the month before delivery may be associated with an increased risk of postpartum hemorrhage <content styleCode="italics">[see Warnings and Precautions (5.5)]</content>.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal adverse reactions</content>
                        </paragraph>
                        <paragraph>NeonatesÂ exposedÂ toÂ paroxetineÂ andÂ otherÂ SSRIsÂ lateÂ inÂ theÂ thirdÂ trimesterÂ haveÂ developed complicationsÂ requiringÂ prolongedÂ hospitalization,Â respiratoryÂ support,Â andÂ tubeÂ feeding.Â Such complicationsÂ canÂ ariseÂ immediatelyÂ uponÂ delivery.Â ReportedÂ clinicalÂ findingsÂ haveÂ included respiratoryÂ distress,Â cyanosis,Â apnea,Â seizures,Â temperatureÂ instability,Â feedingÂ difficulty,Â vomiting, hypoglycemia,Â hypotonia,Â hypertonia,Â hyperreflexia,Â tremors,Â jitteriness,Â irritability,Â andÂ constant crying.Â TheseÂ findingsÂ areÂ consistentÂ withÂ eitherÂ aÂ directÂ toxicÂ effectÂ ofÂ SSRIsÂ orÂ possiblyÂ aÂ drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.</paragraph>
                        <paragraph> Â  </paragraph>
                        <paragraph>Data</paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>PublishedÂ epidemiologicalÂ studiesÂ onÂ theÂ associationÂ betweenÂ firstÂ trimesterÂ paroxetineÂ useÂ and cardiovascularÂ malformationsÂ haveÂ reportedÂ inconsistentÂ results;Â however,Â meta-analysesÂ of population-basedÂ cohortÂ studiesÂ publishedÂ betweenÂ 1996Â âÂ 2017Â indicateÂ aÂ lessÂ thanÂ 2-fold increasedÂ riskÂ forÂ overallÂ cardiovascularÂ malformations.Â SpecificÂ cardiacÂ malformationsÂ identified inÂ twoÂ meta-analysesÂ includeÂ anÂ approximatelyÂ 2Â toÂ 2.5-foldÂ increasedÂ riskÂ forÂ rightÂ ventricular outflowÂ tractÂ defects.Â OneÂ meta-analysisÂ alsoÂ identifiedÂ anÂ increasedÂ riskÂ (lessÂ thanÂ 2-fold)Â for bulbusÂ cordisÂ anomaliesÂ andÂ anomaliesÂ ofÂ cardiacÂ septalÂ closure,Â andÂ anÂ increasedÂ riskÂ forÂ atrial septalÂ defectÂ (pooledÂ ORÂ 2.38,Â 95%Â CIÂ 1.14-4.97).Â ImportantÂ limitationsÂ ofÂ theÂ studiesÂ includedÂ in theseÂ meta-analysesÂ includeÂ potentialÂ confoundingÂ byÂ indication,Â depressionÂ severity,Â andÂ potential exposure misclassification.</paragraph>
                        <br/>
                        <paragraph>ExposureÂ toÂ SSRIs,Â particularlyÂ laterÂ inÂ pregnancy,Â mayÂ haveÂ anÂ increasedÂ riskÂ forÂ PPHN.Â PPHNÂ occurs inÂ 1-2Â perÂ 1000Â liveÂ birthsÂ inÂ theÂ generalÂ populationÂ andÂ isÂ associatedÂ withÂ substantialÂ neonatal morbidity and mortality.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Reproduction studies were performed at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits administered during organogenesis. These doses are approximately 8 (rat) and less than 2 (rabbit) times the maximum recommended human dose (MRHD â 60 mg) on an mg/m<sup>2 </sup>basis. These studies have revealed no evidence of developmental effects. However, in rats, there was an increase in pup deaths during the first 4 days of lactation when dosing occurred during the last trimester of gestation and continued throughout lactation. This effect occurred at a dose of 1 mg/kg/day which is less than the MRHD on an mg/m<sup>2 </sup>basis. The no-effect dose for rat pup mortality was not determined. The cause of these deaths is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="65e807dc-d523-4a35-b939-9e231fad469f"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>Â </paragraph>
                        <paragraph>DataÂ fromÂ theÂ publishedÂ literatureÂ reportÂ theÂ presenceÂ ofÂ paroxetineÂ inÂ humanÂ milkÂ <content styleCode="italics">(seeÂ Data)</content>.Â There areÂ reportsÂ ofÂ agitation,Â irritability,Â poorÂ feedingÂ andÂ poorÂ weightÂ gainÂ inÂ infantsÂ exposedÂ toÂ paroxetine throughÂ breastÂ milkÂ <content styleCode="italics">(seeÂ ClinicalÂ Considerations).Â </content>ThereÂ areÂ noÂ dataÂ onÂ theÂ effectÂ ofÂ paroxetineÂ on milkÂ production.Â TheÂ developmentalÂ andÂ healthÂ benefitsÂ ofÂ breastfeedingÂ shouldÂ beÂ considered alongÂ withÂ theÂ motherâsÂ clinicalÂ needÂ forÂ paroxetineÂ andÂ anyÂ potentialÂ adverseÂ effectsÂ onÂ theÂ breastfed childÂ from paroxetineÂ or fromÂ underlying maternal condition.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Infants exposed to paroxetine should be monitored for agitation, irritability, poor feeding and poor weight gain.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>PublishedÂ literatureÂ suggestsÂ theÂ presenceÂ ofÂ paroxetineÂ inÂ humanÂ milkÂ withÂ relativeÂ infantÂ doses rangingÂ betweenÂ 0.4% to 2.2%,Â and a milk/plasmaÂ ratioÂ ofÂ &lt;1. NoÂ significant amounts wereÂ detected in the plasma of infants after breastfeeding.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="19a6887e-33ae-4f1d-bd95-b6b8cde4e9d6"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Infertility</paragraph>
                        <paragraph>
                           <content styleCode="italics">Male</content>
                        </paragraph>
                        <paragraph>BasedÂ onÂ findingsÂ fromÂ clinicalÂ studies,Â paroxetineÂ mayÂ affectÂ spermÂ qualityÂ whichÂ mayÂ impair fertility; it is not known if this effect is reversible <content styleCode="italics">[see Nonclinical Toxicology (13.1)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="87293560-4272-4b6a-abbb-d40374ca9532"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of paroxetine oral suspension in pediatric patients have not been established <content styleCode="italics">[see Box Warning]. </content>Effectiveness was not demonstrated in three placebo-controlled trials in 752 paroxetine-treated pediatric patients with MDD.</paragraph>
                        <br/>
                        <paragraph>Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (5.1)]</content>. Decreased appetite and weight loss have been observed in association with the use of SSRIs.</paragraph>
                        <br/>
                        <paragraph>In placebo-controlled clinical trials conducted with pediatric patients, the following adverse reactions were reported in at least 2% of pediatric patients treated with paroxetine and occurred at a rate at least twice that for pediatric patients receiving placebo: emotional lability (including self-harm, suicidal thoughts, attempted suicide, crying, and mood fluctuations), hostility, decreased appetite, tremor, sweating, hyperkinesia, and agitation.</paragraph>
                        <br/>
                        <paragraph>Adverse reactions upon discontinuation of treatment with paroxetine in the pediatric clinical trials that included a taper phase regimen, which occurred in at least 2% of patients and at a rate at least twice that of placebo, were: emotional lability (including suicidal ideation, suicide attempt, mood changes, and tearfulness), nervousness, dizziness, nausea, and abdominal pain.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="1696c2af-d2ef-49de-8d2e-17e51f3a9608"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In premarketing clinical trials with paroxetine, 17% of patients treated with paroxetine (approximately 700) were 65 years of age or older. Pharmacokinetic studies revealed a decreased clearance in the elderly, and a lower starting dose is recommended; however, no overall differences in safety or effectiveness were observed between elderly and younger patients <content styleCode="italics">[see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Â </content>
                        </paragraph>
                        <paragraph>SSRIs including paroxetine, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction <content styleCode="italics">[see Warnings and Precautions (5.7)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="c179a124-5743-467b-9fd7-ade776e2c1be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.6 Renal and Hepatic Impairment</title>
                     <text>
                        <paragraph>Increased plasma concentrations of paroxetine oral suspensionÂ occur in patients with renal and hepatic impairment. The initial dosage of paroxetine oral suspension should be reduced in patients with severe renal impairment and in patients with severe hepatic impairment <content styleCode="italics">[see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="5de240c0-33fd-482d-9801-a22043a164fd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The following have been reported with paroxetine overdosage: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Seizures, which may be delayed, and altered mental status including coma. </item>
                     <item>Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation. Hypertension most commonly seen, but rarely can see hypotension alone or with co-ingestants including alcohol. </item>
                     <item>Serotonin syndrome (patients with a multiple drug overdosage with other proserotonergic drugs may have a higher risk). </item>
                  </list>
                  <br/>
                  <paragraph>Gastrointestinal decontamination with activated charcoal should be considered in patients who present early after a paroxetine overdose.</paragraph>
                  <br/>
                  <paragraph>Consider contacting a poison center (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250313"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="3fbee6cc-3876-42c9-a984-59b53f7c3009"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Paroxetine Oral Suspension contains paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-<content styleCode="italics">trans</content>-4<content styleCode="italics">R</content>-(4'-fluorophenyl)-3<content styleCode="italics">S</content>-[(3',4'Â­methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C<sub>19</sub>H<sub>20</sub>FNO<sub>3</sub>â¢HClâ¢1/2H<sub>2</sub>O. The molecular weight is 374.8 (329.4 as free base). The structural formula of paroxetine hydrochloride is:</paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM7"/>
                  <br/>
                  <paragraph>Paroxetine hydrochloride is an odorless, off-white powder, having a melting point range of 120Â° to 138Â°C and a solubility of 5.4 mg/mL in water.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Paroxetine Oral Suspension</content>
                  </paragraph>
                  <paragraph>Paroxetine Oral Suspension is for oral administration. Each 5 mL contains 10 mg of paroxetine equivalent to 11.1 mg of paroxetine hydrochloride.</paragraph>
                  <br/>
                  <paragraph>Inactive ingredients consist of polacrilin potassium, microcrystalline cellulose, carboxymethyl cellulose sodium, propylene glycol, glycerin, sorbitol, methylparaben, propylparaben, sodium citrate dihydrate, citric acid anhydrous, sodium saccharin, orange flavor (triacetin, propylene glycol, natural and artificial flavor), FD&amp;C Yellow No. 6, simethicone emulsion and purified water.</paragraph>
               </text>
               <effectiveTime value="20250313"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="05b281e2-394d-41ea-be2f-82de556d345a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250313"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="04ccd430-e4b0-4396-8010-12add9b7690e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism of action of paroxetine in the treatment of MDD, SAD, OCD, PD, GAD, and PTSD is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-hydroxy-tryptamine, 5-HT).</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="bd2c49b2-54c8-458d-a85b-17866d9e36a2"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Studies at clinically relevant doses in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets. In vitro studies in animals also suggest that paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake (SSRI) and has only very weak effects on norepinephrine and dopamine neuronal reuptake.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="1c769c2c-3e1a-4389-b044-588c5a3dada3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Nonlinearity in pharmacokinetics is observed with increasing doses of paroxetine.</paragraph>
                        <br/>
                        <paragraph>In a meta-analysis of paroxetine from 4 studies done in healthy volunteers following multiple dosing of 20 mg/day to 40 mg/day, males did not exhibit a significantly lower C<sub>max</sub> or AUC than females.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Absorption </content>
                        </paragraph>
                        <paragraph>Paroxetine hydrochloride is completely absorbed after oral dosing of a solution of the hydrochloride salt. In a study in which normal male subjects (n = 15) received 30 mg tablets daily for 30 days, steady-state paroxetine concentrations were achieved by approximately 10 days for most subjects, although it may take substantially longer in an occasional patient. At steady state, mean values of C<sub>max</sub>, T<sub>max</sub>, C<sub>min</sub>, and T<sub>Â½ </sub>were 61.7 ng/mL (CV 45%), 5.2 hr. (CV 10%), 30.7 ng/mL (CV 67%), and 21 hours (CV 32%), respectively. The steady-state C<sub>max</sub> and C<sub>min</sub> values were about 6 and 14 times what would be predicted from single-dose studies. Steady-state drug exposure based on AUC<sub>0-24</sub> was about 8 times greater than would have been predicted from single-dose data in these subjects. The excess accumulation is a consequence of the fact that 1 of the enzymes that metabolizes paroxetine is readily saturable.</paragraph>
                        <br/>
                        <paragraph>Paroxetine is equally bioavailable from the oral suspension and tablet.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>The effects of food on the bioavailability of paroxetine were studied in subjects administered a single dose with and without food. AUC was only slightly increased (6%) when drug was administered with food but the C<sub>max</sub> was 29% greater, while the time to reach peak plasma concentration decreased from 6.4 hours post-dosing to 4.9 hours.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Paroxetine distributes throughout the body, including the CNS, with only 1% remaining in the plasma.</paragraph>
                        <br/>
                        <paragraph>Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical conditions, paroxetine concentrations would normally be less than 400 ng/mL. Paroxetine does not alter the <content styleCode="italics">in vitro </content>protein binding of phenytoin or warfarin.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Elimination </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism </content>
                        </paragraph>
                        <paragraph>The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.</paragraph>
                        <br/>
                        <paragraph>In steady-state dose proportionality studies involving elderly and nonelderly patients, at doses of 20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, some nonlinearity was observed in both populations, again reflecting a saturable metabolic pathway. In comparison to C<sub>min</sub> values after 20 mg daily, values after 40 mg daily were only about 2 to 3 times greater than doubled.</paragraph>
                        <br/>
                        <paragraph>Paroxetine is extensively metabolized after oral administration. The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared. Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified. Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake. The metabolism of paroxetine is accomplished in part by CYP2D6. Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment. The role of this enzyme in paroxetine metabolism also suggests potential drug-drug interactions <content styleCode="italics">[see Drug Interactions (7)]</content>. Pharmacokinetic behavior of paroxetine has not been evaluated in subjects who are deficient in CYP2D6 (poor metabolizers).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Excretion </content>
                        </paragraph>
                        <paragraph>Approximately 64% of a 30-mg oral solution dose of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10-day post-dosing period. About 36% was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% as the parent compound over the 10-day post-dosing period.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>There are clinically significant, known drug interactions between paroxetine and other drugs <content styleCode="italics">[see Drug Interactions (7)].<br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1. Impact of Paroxetine on the Pharmacokinetics of Co-Administered Drugs (log scale)<br/>
                           </content>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM8"/>
                              <br/> Figure 2. Impact of Co-Administered Drugs on the Pharmacokinetics of Paroxetine<br/>
                              <renderMultiMedia referencedObject="MM9"/>
                              <br/>
                           </content>
                           <content styleCode="underline">
                              <br/> Theophylline:</content> Reports of elevated theophylline levels associated with paroxetine treatment have been reported. While this interaction has not been formally studied, it is recommended that theophylline levels be monitored when these drugs are concurrently administered.<br/>
                           <br/>
                           <content styleCode="italics">Drugs Metabolized by Cytochrome CYP3A4</content>
                           <br/>An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, triazolam, and cyclosporine. Paroxetineâs extent of inhibition of CYP3A4 activity is not expected to be of clinical significance.<br/>
                           <content styleCode="underline">
                              <br/> Specific Populations<br/>
                           </content>The impact of specific populations on the pharmacokinetics of paroxetine are shown in Figure 3.<br/>The recommended starting dosage and maximum dosage of paroxetine is reduced in elderly patients, patients with severe renal impairment, and patients with severe hepatic impairment [see Dosage and Administration (2.4)].<br/>
                           <content styleCode="bold">
                              <br/> Figure 3. Impact of Specific Population on the Pharmacokinetics of Paroxetine (log scale)<br/>
                              <renderMultiMedia referencedObject="MM10"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                     <component>
                        <observationMedia ID="MM8">
                           <text>figure-1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM9">
                           <text>figure-2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM10">
                           <text>figure-3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="02c3433e-5557-4413-9a81-2e78bb9c723d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250313"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="41ca5e55-4fe8-4992-be1e-881774ea35ad"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Two-year carcinogenicity studies were conducted in rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day (mice) and 1, 5, and 20 mg/kg/day (rats). These doses are up to 2 (mouse) and 3 (rat) times the MRHD of 60 mg on a mg/m<sup>2 </sup>basis. There was a significantly greater number of male rats in the high-dose group with reticulum cell sarcomas (1/100, 0/50, 0/50, and 4/50 for control, low-, middle-, and high-dose groups, respectively) and a significantly increased linear trend across dose groups for the occurrence of lymphoreticular tumors in male rats. Female rats were not affected. Although there was a dose-related increase in the number of tumors in mice, there was no drug-related increase in the number of mice with tumors. The relevance of these findings to humans is unknown.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Paroxetine produced no genotoxic effects in a battery of 5 <content styleCode="italics">in vitro </content>and 2 <content styleCode="italics">in vivo </content>assays that included the following: Bacterial mutation assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations <content styleCode="italics">in vivo </content>in mouse bone marrow and <content styleCode="italics">in vitro </content>in human lymphocytes and in a dominant lethal test in rats.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>A reduced pregnancy rate was found in reproduction studies in rats at a dose of paroxetine of 15 mg/kg/day, which is 2 times the MRHD of 60 mg on a mg/m<sup>2</sup> basis. Irreversible lesions occurred in the reproductive tract of male rats after dosing in toxicity studies for 2 to 52 weeks. These lesions consisted of vacuolation of epididymal tubular epithelium at 50 mg/kg/day and atrophic changes in the seminiferous tubules of the testes with arrested spermatogenesis at 25 mg/kg/day (8 and 4 times the MRHD of 60 mg on a mg/m<sup>2</sup> basis).</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="9b3e5664-efe2-425d-8448-4a208c2e39f0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250313"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="1870d3b2-3c11-4b98-8014-0925c417b4e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.1 Major Depressive Disorder</title>
                     <text>
                        <paragraph>The efficacy of paroxetine as a treatment for major depressive disorder (MDD) has been established in 6 placebo-controlled studies of patients with MDD (aged 18 to 73). In these studies, paroxetine was shown to be statistically significantly more effective than placebo in treating MDD by at least 2 of the following measures: Hamilton Depression Rating Scale (HDRS), the Hamilton depressed mood item, and the Clinical Global Impression (CGI)-Severity of Illness. Paroxetine was statistically significantly better than placebo in improvement of the HDRS sub-factor scores, including the depressed mood item, sleep disturbance factor, and anxiety factor.</paragraph>
                        <br/>
                        <paragraph>Long-term efficacy of paroxetine for treatment of MDD in outpatients was demonstrated in a randomized withdrawal study. Patients who responded to paroxetine (HDRS total score &lt;8) during an initial 8-week open-label treatment phase were then randomized to continue paroxetine or placebo, for up to 1 year. Patients treated with paroxetine demonstrated a statistically significant lower relapse rate during the withdrawal phase (15%) compared to those on placebo (39%). Effectiveness was similar for male and female patients.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="6a0ba05e-50d0-4e6f-851c-6eeddd358a52"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.2 Obsessive Compulsive Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of obsessive compulsive disorder (OCD) was demonstrated in two 12-week multicenter placebo-controlled studies of adult outpatients (Studies 1 and 2). Patients had moderate to severe OCD (DSM-IIIR) with mean baseline ratings on the Yale Brown Obsessive Compulsive Scale (YBOCS) total score ranging from 23 to 26. In study 1, a dose-range finding study, patients received fixed daily doses of paroxetine 20 mg, 40 mg, or 60 mg. Study 1 demonstrated that daily doses of paroxetine 40 mg and 60 mg are effective in the treatment of OCD. Patients receiving doses of paroxetine 40 mg and 60 mg experienced a mean reduction of approximately 6 and 7 points, respectively, on the YBOCS total score which was statistically significantly greater than the approximate 4-point reduction at 20 mg and a 3-point reduction in the placebo-treated patients. Study 2 was a flexible-dose study comparing paroxetine 20 mg to 60 mg daily with clomipramine 25 mg to 250 mg daily or placebo). In this study, patients receiving paroxetine experienced a mean reduction of approximately 7 points on the YBOCS total score, which was statistically significantly greater than the mean reduction of approximately 4 points in placebo-treated patients.</paragraph>
                        <br/>
                        <paragraph>The following table provides the outcome classification by treatment group on Global Improvement items of the Clinical Global Impression (CGI) scale for Study 1.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 10</content>: <content styleCode="bold">Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1 in Patients with OCD</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="624">
                           <colgroup>
                              <col width="26.1538461538462%"/>
                              <col width="18.4615384615385%"/>
                              <col width="18.4615384615385%"/>
                              <col width="18.4615384615385%"/>
                              <col width="18.4615384615385%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Outcome Classification</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(n = 74)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Paroxetine</content>
                                    <br/>
                                    <content styleCode="bold">20 mg</content>
                                    <br/>
                                    <content styleCode="bold">(n = 75)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Paroxetine</content>
                                    <br/>
                                    <content styleCode="bold">40 mg</content>
                                    <br/>
                                    <content styleCode="bold">(n = 66)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Paroxetine</content>
                                    <br/>
                                    <content styleCode="bold">60 mg</content>
                                    <br/>
                                    <content styleCode="bold">(n = 66)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Worse<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">No Change<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">44<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">35<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">19<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Minimally Improved<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">33<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">29<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">34<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Much Improved<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">18<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Very Much Improved<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.</paragraph>
                        <br/>
                        <paragraph>The long-term efficacy of paroxetine for the treatment of OCD was established in a long-term extension to Study 1. Patients who responded to paroxetine during the 3-month double-blind phase and a 6-month extension on open-label paroxetine 20 mg to 60 mg daily were randomized to either paroxetine or placebo in a 6-month double-blind relapse prevention phase. Patients randomized to paroxetine were statistically significantly less likely to relapse than placebo-treated patients.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.3">
                     <id root="ee8d5b3e-3b3c-42c7-8ae3-5a1438b0deaf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.3 Panic Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of panic disorder (PD) was demonstrated in three 10- to 12-week multicenter, placebo-controlled studies of adult outpatients (Studies 1, 2, and 3). Patients had PD (DSM-IIIR), with or without agoraphobia. In these studies, paroxetine was shown to be statistically significantly more effective than placebo in treating PD by at least 2 out of 3 measures of panic attack frequency and on the Clinical Global Impression Severity of Illness score.</paragraph>
                        <br/>
                        <paragraph>Study 1 was a 10-week dose-range finding study; patients received fixed doses of paroxetine 10 mg, 20 mg, or 40 mg daily or placebo. A statistically significant difference from placebo was observed only for the paroxetine 40 mg daily group. At endpoint, 76% of patients receiving paroxetine 40 mg daily were free of panic attacks, compared to 44% of placebo-treated patients.</paragraph>
                        <br/>
                        <paragraph>Study 2 was a 12-week flexible-dose study comparing paroxetine 10 mg to 60 mg daily and placebo. At endpoint, 51% of paroxetine-treated patients were free of panic attacks compared to 32% of placebo-treated patients.</paragraph>
                        <br/>
                        <paragraph>Study 3 was a 12-week flexible-dose study comparing paroxetine 10 mg to 60 mg daily to placebo in patients concurrently receiving standardized cognitive behavioral therapy. At endpoint, 33% of the paroxetine-treated patients showed a reduction to 0 or 1 panic attacks compared to 14% of placebo-treated patients.</paragraph>
                        <br/>
                        <paragraph>In Studies 2 and 3, the mean paroxetine dose for completers at endpoint was approximately 40 mg daily.</paragraph>
                        <br/>
                        <paragraph>Long-term efficacy of paroxetine in PD was demonstrated in an extension to Study 1. Patients who responded to paroxetine during the 10-week double-blind phase and during a 3-month double-blind extension phase were randomized to either paroxetine 10 mg, 20 mg, or 40 mg daily or placebo in a 3-month double-blind relapse prevention phase. Patients randomized to paroxetine were statistically significantly less likely to relapse than placebo-treated patients.</paragraph>
                        <br/>
                        <paragraph>Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.4">
                     <id root="ead5158d-96ee-4855-bdf2-b31445f6774d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.4 Social Anxiety Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of social anxiety disorder (SAD) was demonstrated in three 12-week, multicenter, placebo-controlled studies (Studies 1, 2, and 3) of adult outpatients with SAD (DSM-IV). In these studies, the effectiveness of paroxetine compared to placebo was evaluated on the basis of (1) the proportion of responders, as defined by a Clinical Global Impression (CGI) Improvement score of 1 (very much improved) or 2 (much improved), and (2) change from baseline in the Liebowitz Social Anxiety Scale (LSAS).</paragraph>
                        <br/>
                        <paragraph>Studies 1 and 2 were flexible-dose studies comparing paroxetine 20 mg to 50 mg daily and placebo. Paroxetine demonstrated statistically significant superiority over placebo on both the CGI Improvement responder criterion and the Liebowitz Social Anxiety Scale (LSAS). In Study 1, for patients who completed to week 12, 69% of paroxetine-treated patients compared to 29% of placebo-treated patients were CGI Improvement responders. In Study 2, CGI Improvement responders were 77% and 42% for the paroxetine- and placebo-treated patients, respectively.</paragraph>
                        <br/>
                        <paragraph>Study 3 was a 12-week study comparing fixed doses of paroxetine 20 mg, 40 mg, or 60 mg daily with placebo. Paroxetine 20 mg was statistically significantly superior to placebo on both the LSAS Total Score and the CGI Improvement responder criterion; there were trends for superiority over placebo for the paroxetine 40 mg and 60 mg daily dose groups. There was no indication in this study of any additional benefit for doses higher than 20 mg daily.</paragraph>
                        <br/>
                        <paragraph>Subgroup analyses generally did not indicate differences in treatment outcomes as a function of age, race, or gender.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.5">
                     <id root="f470a3fc-9eef-4c7d-8795-4909e62e9ef3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.5 Generalized Anxiety Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of generalized anxiety disorder (GAD) was demonstrated in two 8-week, multicenter, placebo-controlled studies (Studies 1 and 2) of adult outpatients with GAD (DSM-IV).</paragraph>
                        <br/>
                        <paragraph>Study 1 was an 8-week study comparing fixed doses of paroxetine 20 mg or 40 mg daily with placebo. Doses of paroxetine 20 mg or 40 mg were both demonstrated to be statistically significantly superior to placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score. There was not sufficient evidence in this study to suggest a greater benefit for the paroxetine 40 mg daily dose compared to the 20 mg daily dose.</paragraph>
                        <br/>
                        <paragraph>Study 2 was a flexible-dose study comparing paroxetine 20 mg to 50 mg daily and placebo. Paroxetine demonstrated statistically significant superiority over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score.</paragraph>
                        <br/>
                        <paragraph>A third study, a flexible-dose study comparing paroxetine 20 mg to 50 mg daily to placebo, did not demonstrate statistically significant superiority of paroxetine over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score, the primary outcome.</paragraph>
                        <br/>
                        <paragraph>Subgroup analyses did not indicate differences in treatment outcomes as a function of race or gender. There were insufficient elderly patients to conduct subgroup analyses on the basis of age.</paragraph>
                        <br/>
                        <paragraph>In a long-term trial, 566 patients meeting DSM-IV criteria for GAD, who had responded during a single-blind, 8-week acute treatment phase with paroxetine 20 mg to 50 mg daily, were randomized to continuation of paroxetine at their same dose, or to placebo, for up to 24 weeks of observation for relapse. Response during the single-blind phase was defined by having a decrease of <content styleCode="underline">&gt;</content>2 points compared to baseline on the CGI-Severity of Illness scale, to a score of <content styleCode="underline">&lt;</content>3. Relapse during the double-blind phase was defined as an increase of <content styleCode="underline">&gt;</content>2 points compared to baseline on the CGI-Severity of Illness scale to a score of <content styleCode="underline">&gt;</content>4, or withdrawal due to lack of efficacy. Patients continuing to receive paroxetine experienced a statistically significantly lower relapse rate over the subsequent 24 weeks compared to those receiving placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.6">
                     <id root="289519e7-0b46-485f-9b51-e693b158d399"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.6 Posttraumatic Stress Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of Posttraumatic Stress Disorder (PTSD) was demonstrated in two 12-week, multicenter, placebo-controlled studies (Studies 1 and 2) of adult outpatients who met DSM-IV criteria for PTSD. The mean duration of PTSD symptoms for the 2 studies combined was 13 years (ranging from 0.1 year to 57 years). The percentage of patients with secondary MDD or non-PTSD anxiety disorders in the combined 2 studies was 41% (356 out of 858 patients) and 40% (345 out of 858 patients), respectively. Study outcome was assessed by (1) the Clinician-Administered PTSD Scale Part 2 (CAPS-2) score and (2) the Clinical Global Impression-Global Improvement Scale (CGI-I). The CAPS-2 is a multi-item instrument that measures 3 aspects of PTSD with the following symptom clusters: Reexperiencing/intrusion, avoidance/numbing and hyperarousal. The 2 primary outcomes for each trial were (1) change from baseline to endpoint on the CAPS-2 total score (17 items), and (2) proportion of responders on the CGI-I, where responders were defined as patients having a score of 1 (very much improved) or 2 (much improved).</paragraph>
                        <br/>
                        <paragraph>Study 1 was a 12-week study comparing fixed doses of paroxetine 20 mg or 40 mg daily to placebo. Doses of paroxetine 20 mg and 40 mg were demonstrated to be statistically significantly superior to placebo on change from baseline for the CAPS-2 total score and on proportion of responders on the CGI-I. There was not sufficient evidence in this study to suggest a greater benefit for the 40 mg daily dose compared to the 20 mg daily dose.</paragraph>
                        <br/>
                        <paragraph>Study 2 was a 12-week flexible-dose study comparing paroxetine 20 mg to 50 mg daily to placebo. Paroxetine was demonstrated to be significantly superior to placebo on change from baseline for the CAPS-2 total score and on proportion of responders on the CGI-I.</paragraph>
                        <br/>
                        <paragraph>A third study, a flexible-dose study comparing paroxetine 20 mg to 50 mg daily to placebo, demonstrated paroxetine to be statistically significantly superior to placebo on change from baseline for CAPS-2 total score, but not on proportion of responders on the CGI-I.</paragraph>
                        <br/>
                        <paragraph>The majority of patients in these trials were women (68% women: 377 out of 551 subjects in Study 1 and 66% women: 202 out of 303 subjects in Study 2). Subgroup analyses did not indicate differences in treatment outcomes as a function of gender. There were an insufficient number of patients who were 65 years and older or were non-Caucasian to conduct subgroup analyses on the basis of age or race, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="e0ce3368-a1ef-47db-81ce-0db40946d784"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Paroxetine Oral Suspension is supplied as:</paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="623">
                     <colgroup>
                        <col width="16.6720136883756%"/>
                        <col width="22.7462303496952%"/>
                        <col width="33.3440273767511%"/>
                        <col width="27.2377285851781%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="middle">
                              <content styleCode="bold">Strength</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">Color/Flavor</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">Package Configuration</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">NDC Number</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="center" valign="middle">10 mg/5 mL<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">Orange/orange<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">Bottles containing 250 mL<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">70954-319-10<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
                  <paragraph>Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250313"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="6a74552a-26f5-4eef-b061-4cfefa73240e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Suicidal Thoughts and Behaviors</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down, and instruct them to report such symptoms to the healthcare provider <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (5.1)]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of paroxetine oral suspensionÂ with other serotonergic drugs including triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, St. Johnâs Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome <content styleCode="italics">[see Warnings </content>and <content styleCode="italics">Precautions (5.2), Drug Interactions (7)]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Concomitant Medications</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for drug-drug interactions <content styleCode="italics">[see Warning and Precautions (5.3), Drug Interactions (7)]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Increased Risk of Bleeding</content>
                  </paragraph>
                  <paragraph>Inform patients about the concomitant use of paroxetine oral suspensionÂ with aspirin, NSAIDs, other antiplatelet drugs, warfarin, or other anticoagulants because the combined use has been associated with an increased risk of bleeding. Advise patients to inform their health care providers if they are taking or planning to take any prescription or over-the counter medications that increase the risk of bleeding <content styleCode="italics">[see Warnings and Precautions (5.5)].</content>
                  </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Activation of Mania/Hypomania</content>
                  </paragraph>
                  <paragraph>Advise patients and their caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider <content styleCode="italics">[see Warnings and Precautions (5.6)]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Discontinuation Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients not to abruptly discontinue paroxetine oral suspensionÂ and to discuss any tapering regimen with their healthcare provider. Inform patients that adverse reactions can occur when paroxetine oral suspensionÂ is discontinued <content styleCode="italics">[See Warnings and Precautions (5.7)].</content>
                  </paragraph>
                  <br/>
                  <paragraph>Sexual Dysfunction</paragraph>
                  <paragraph>Advise patients that use of paroxetine may cause symptoms of sexual dysfunction in both male and female patients. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider <content styleCode="italics">[see Warnings and Precautions (5.13)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Â </content>
                  </paragraph>
                  <paragraph>Administration Information for Oral Suspension</paragraph>
                  <paragraph>Instruct patients to shake the oral suspension well before administration <content styleCode="italics">[see Dosage and Administration (2.1)].</content>
                  </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to notify their healthcare provider if they develop an allergic reaction such as rash, hives, swelling, or difficulty breathing <content styleCode="italics">[see Adverse Reactions (6.1, 6.2)]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">EmbryoFetal Toxicity</content>
                  </paragraph>
                  <paragraph>AdviseÂ womenÂ toÂ notifyÂ theirÂ healthcareÂ providerÂ ifÂ theyÂ becomeÂ pregnantÂ orÂ intendÂ toÂ becomeÂ pregnant during treatment with paroxetine. Advise women of risks associated with first trimester useÂ ofÂ paroxetineÂ andÂ thatÂ useÂ laterÂ inÂ pregnancyÂ mayÂ leadÂ toÂ anÂ increasedÂ riskÂ forÂ neonatalÂ complicationsÂ requiringÂ prolongedÂ hospitalization,Â respiratoryÂ support,Â tubeÂ feeding,Â and/orÂ persistentÂ pulmonaryÂ hypertensionÂ ofÂ theÂ newbornÂ (PPHN)Â <content styleCode="italics">[seeÂ WarningsÂ andÂ PrecautionsÂ (5.4),Â UseÂ inÂ SpecificÂ PopulationsÂ (8.1)].Â </content>AdviseÂ womenÂ thatÂ thereÂ isÂ aÂ pregnancyÂ exposureÂ registryÂ thatÂ monitors pregnancyÂ outcomesÂ inÂ womenÂ exposedÂ toÂ paroxetineÂ duringÂ pregnancyÂ <content styleCode="italics">[seeÂ WarningsÂ and Precautions (5.4), Use in Specific Populations (8.1)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Â </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>AdviseÂ breastfeedingÂ womenÂ usingÂ paroxetineÂ toÂ monitorÂ infantsÂ forÂ agitation,Â irritability,Â poor feeding,Â andÂ poorÂ weightÂ gainÂ andÂ toÂ seekÂ medicalÂ careÂ ifÂ theyÂ noticeÂ theseÂ signsÂ <content styleCode="italics">[seeÂ UseÂ in Specific Populations (8.2)]</content>.</paragraph>
                  <paragraph> Â  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Females and Males of Reproductive Potential</content>
                  </paragraph>
                  <paragraph>AdviseÂ men thatÂ paroxetineÂ mayÂ affect spermÂ quality,Â whichÂ may impairÂ fertility; itÂ isÂ notÂ known if this effect is reversible <content styleCode="italics">[see Use in Specific Populations (8.3)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Â </content>
                  </paragraph>
                  <br/>
                  <paragraph>All trademarks are the property of their respective owners.</paragraph>
                  <br/>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Novitium Pharma LLC</content>
                  </paragraph>
                  <paragraph>70 Lake Drive, East Windsor</paragraph>
                  <paragraph>New Jersey 08520</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Issued:</content>Â 03/2025</paragraph>
                  <paragraph>Â LB4256-06</paragraph>
               </text>
               <effectiveTime value="20250313"/>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_1">
               <id root="556099d4-5271-4270-8cf3-1236110e071d"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>SPL MEDGUIDE SECTION</title>
               <text>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="599.564">
                     <colgroup>
                        <col width="100%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="top">Â <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>Â <content styleCode="bold">Paroxetine <content styleCode="bold">(pa roxâ e teen)</content>
                              </content>
                              <br/>Â <content styleCode="bold">Oral Suspension</content>
                              <br/>Â </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">What is the most important information I should know about <content styleCode="bold">paroxetine oral suspension</content>?</content>
                              <br/>Â <content styleCode="bold">Paroxetine oral suspension can cause serious side effects, including:</content>
                              <br/>Â <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Increased risk of suicidal thoughts or actions. </content>Paroxetine oral suspension and other antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the <content styleCode="bold">first few months of treatment or when the dose is changed</content>. <content styleCode="bold">Paroxetine oral suspension is not for use in children.</content>
                                 </item>
                              </list>Â <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Depression or other mental illnesses are the most important causes of suicidal thoughts and actions.</content>
                                 </item>
                              </list>Â <content styleCode="bold">How can I watch for and try to prevent suicidal thoughts and actions?</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts or feelings or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed.</item>
                                 <item>Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings or if you develop suicidal thoughts or actions.</item>
                                 <item>Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.<br/>
                                    <br/>Â </item>
                              </list>
                              <content styleCode="bold">Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms, especially if they are new, worse, or worry you:</content>
                              <br/>
                              <renderMultiMedia referencedObject="MM11"/>Â Â </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">What is paroxetine oral suspension?</content>
                              <br/>Â Paroxetine oral suspension is a prescription medicine used in adults to treat:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>A certain type of depression called Major Depressive Disorder (MDD)</item>
                                 <item>Obsessive Compulsive Disorder (OCD)</item>
                                 <item>Panic Disorder (PD)</item>
                                 <item>Social Anxiety Disorder (SAD)</item>
                                 <item>Generalized Anxiety Disorder (GAD)</item>
                                 <item>Posttraumatic Stress Disorder (PTSD)</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">Do not take paroxetine oral suspension if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Â </content>take a monoamine oxidase inhibitor (MAOI)</item>
                                 <item>have stopped taking an MAOI in the last 14 days</item>
                                 <item>are being treated with the antibiotic linezolid or the intravenous methylene blue</item>
                                 <item>are taking pimozide</item>
                                 <item>are taking thioridazine</item>
                                 <item>are allergic to paroxetine or any of the ingredients in paroxetine oral suspension. See the end of this Medication Guide for a complete list of ingredients in paroxetine oral suspension.</item>
                              </list>Â <br/>Â Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI or one of these medicines, including the antibiotic linezolid or intravenous methylene blue.<br/>Â Â <br/>Â <content styleCode="bold">Do not start taking an MAOI for at least 14 days after you stop treatment with </content>
                              <content styleCode="bold">paroxetine oral suspension.</content>
                              <br/>Â </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">Before taking paroxetine oral suspension, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <br/>Â <list listType="unordered" styleCode="disc">
                                 <item>have heart problemshave or had bleeding problems<br/>
                                 </item>
                                 <item>have, or have a family history of, bipolar disorder, mania or hypomania</item>
                                 <item>have or had seizures or convulsions</item>
                                 <item>have glaucoma (high pressure in the eye)</item>
                                 <item>have low sodium levels in your blood</item>
                                 <item>have bone problems</item>
                                 <item>have kidney or liver problems</item>
                                 <item>Â are pregnant or plan to become pregnant. Paroxetine may harm your unborn baby.</item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>Taking paroxetine oral suspension during your first trimester of pregnancy may cause your baby to be at an increased risk of having a heart problem (cardiac malformations) at birth.</item>
                                 <item>Taking paroxetine oral suspension during your third trimester of pregnancy may cause your baby to have breathing, temperature, and feeding problems, low muscle tone, and irritability after birth and may cause your baby to be at an increased risk of a serious lung problem at birth. Talk to your healthcare provider about the risk to your unborn baby if you take paroxetine during pregnancy.</item>
                                 <item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with paroxetine oral suspension.</item>
                                 <item>There is a pregnancy registry for females who are exposed to paroxetine during pregnancy. The purpose of the registry is to collect information about the health of females exposed to paroxetine and their baby. If you become pregnant during treatment with paroxetine oral suspension, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry /antidepressants/.</item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>are breastfeeding or plan to breastfeed. Paroxetine passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with paroxetine oral suspension.</item>
                              </list>Â <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br/>Â <br/>Â Paroxetine oral suspension and some other medicines may affect each other causing possible serious side effects. Paroxetine oral suspension may affect the way other medicines work and other medicines may affect the way paroxetine oral suspensionÂ works.<br/>Â <br/>Â <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>medicines used to treat migraine headaches called triptans<br/>
                                 </item>
                                 <item>tricyclic antidepressants<br/>
                                 </item>
                                 <item>lithium<br/>
                                 </item>
                                 <item>tramadol, fentanyl, meperidine, methadone, or other opioids</item>
                                 <item>tryptophan</item>
                                 <item>buspirone</item>
                                 <item>amphetamines</item>
                                 <item>St. Johnâs Wort<br/>
                                 </item>
                                 <item>medicines that can affect blood clotting such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin<br/>
                                 </item>
                                 <item>diuretics<br/>
                                 </item>
                                 <item>tamoxifen<br/>
                                 </item>
                                 <item>medicines used to treat mood, anxiety, psychotic, or thought disorders, including selective serontonin reuptake (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs)<br/>
                                 </item>
                              </list>Â Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take paroxetine oral suspensionÂ with your other medicines.<br/>Â Â <br/>Â Do not start or stop any other medicines during treatment with paroxetine oral suspensionÂ without talking to your healthcare provider first. Stopping paroxetine oral suspensionÂ suddenly may cause you to have serious side effects. See, <content styleCode="bold">âWhat are the possible side effects of </content>
                              <content styleCode="bold">paroxetine oral suspension?â.</content>
                              <br/>Â Â <br/>Â Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.<br/>Â </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">How should I take </content>
                              <content styleCode="bold">paroxetine oral suspension?</content>
                              <br/>Â <list listType="unordered" styleCode="disc">
                                 <item>Take paroxetine oral suspensionÂ exactly as prescribed. Your healthcare provider may need to change the dose of paroxetine oral suspensionÂ until it is the right dose for you.</item>
                                 <item>Take paroxetine oral suspensionÂ 1 time each day in the morning.</item>
                                 <item>Paroxetine oral suspension may be taken with or without food.</item>
                                 <item>If you are taking paroxetine oral suspension, shake the suspension well before taking.</item>
                                 <item>If you take too much paroxetine oral suspension, call your poison control center at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item>
                              </list>Â </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">What are possible side effects of </content>
                              <content styleCode="bold">paroxetine oral suspension?</content>
                              <br/>Â <content styleCode="bold">Paroxetine oral suspension can cause serious side effects, including:</content>
                              <br/>Â <list listType="unordered" styleCode="Disc">
                                 <item>See, <content styleCode="bold">âWhat is the most important information I should know about </content>
                                    <content styleCode="bold">paroxetine oral suspension?â</content>Â <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Serotonin syndrome.</content> A potentially life-threatening problem called serotonin syndrome can happen when you take paroxetine oral suspensionÂ with certain other medicines. See, âWho should not takeÂ paroxetine oral suspension?â <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away</content> if you have any of the following signs and symptoms of serotonin syndrome:</item>
                              </list>
                              <renderMultiMedia referencedObject="MM12"/>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Eye problems (angle-closure glaucoma)</content>. Paroxetine oral suspension may cause a type of eye problem called angle-closure glaucoma in people with certain other eye conditions. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are. Call your healthcare provider if you have eye pain, changes in your vision, or swelling or redness in or around the eye.<br/>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Medicine interactions.</content> Taking paroxetine oral suspensionÂ with certain other medicines including thioridazine and pimozide may increase the risk of developing a serious heart problem called QT prolongation.</item>
                                 <item>Â <content styleCode="bold">Seizures (convulsions).</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Manic episodes. </content>Manic episodes may happen in people with bipolar disorder who take paroxetine oral suspension. Symptoms may include:<br/>
                                 </item>
                              </list>
                              <renderMultiMedia referencedObject="MM13"/>Â              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Discontinuation syndrome.</content> Suddenly stopping paroxetine oral suspensionÂ may cause you to have serious side effects. Your healthcare provider may want to decrease your dose slowly. Symptoms may include:<br/>
                                 </item>
                              </list>
                              <renderMultiMedia referencedObject="MM14"/>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Â <content styleCode="bold">Low sodium levels in your blood (hyponatremia).</content> Low sodium levels in your blood that may be serious and may cause death, can happen during treatment with paroxetine oral suspension. Elderly people and people who take certain medicines may be at a greater risk for developing low sodium levels in your blood. Signs and symptoms may include:<br/>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>headache</item>
                                 <item>difficulty concentrating</item>
                                 <item>memory changes</item>
                                 <item>confusion</item>
                                 <item>weakness and unsteadiness on your feet which can lead to falls</item>
                              </list>
                              <content styleCode="bold">In more severe or more sudden cases, signs and symptoms include:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>seeing or hearing things that are not real (hallucinations)</item>
                                 <item>fainting</item>
                                 <item>seizures</item>
                                 <item>coma</item>
                                 <item>stopping breathing (respiratory arrest)</item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Abnormal bleeding. </content>Taking paroxetine oral suspensionÂ with aspirin, NSAIDs, or blood thinners may increase this risk. Tell your healthcare provider about any unusual bleeding or bruising.</item>
                                 <item>Â <content styleCode="bold">Bone</content>
                                    <content styleCode="bold">fractures.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Sexual problems (dysfunction). </content>Taking selective serotonin reuptake inhibitors (SSRIs), including paroxetine oral suspension, may cause sexual problems.<br/>
                                 </item>
                              </list>Symptoms in males may include:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Delayed ejaculation or inability to have an ejaculation</item>
                                 <item>Decreased sex drive</item>
                                 <item>Problems getting or keeping an erection</item>
                              </list>
                              <br/>Symptoms in females may include:<list listType="unordered" styleCode="disc">
                                 <item>Decreased sex drive</item>
                                 <item>Delayed orgasm or inability to have an orgasm</item>
                              </list>Talk to your healthcare provider if you develop any changes in your sexual function or if you have any questions or concerns about sexual problems during treatment with paroxetine. There may be treatments your healthcare provider can suggest.<br/>Â <br/>Â <content styleCode="bold">The most common side effects of paroxetine oral suspensionÂ include:</content>
                              <br/>
                              <renderMultiMedia referencedObject="MM15"/>
                              <br/>These are not all the possible side effects of paroxetine oral suspension.<br/>Â Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br/>Â </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">How should I store </content>
                              <content styleCode="bold">paroxetine oral suspension?</content>
                              <br/>Â <list listType="unordered" styleCode="Disc">
                                 <item>Store paroxetine oral suspensionÂ at 68Â° to 77ÂºF (20Â° to 25ÂºC).</item>
                              </list>Â <content styleCode="bold">Keep p</content>
                              <content styleCode="bold">aroxetine and all medicines out of the reach of children.</content>
                              <br/>Â </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">General information about the safe and effective use of </content>
                              <content styleCode="bold">paroxetine oral suspension.</content>
                              <br/>Â Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take paroxetine oral suspensionÂ for a condition for which it was not prescribed. Do not give paroxetine oral suspensionÂ to other people, even if they have the same symptoms that you have. It may harm them. You may ask your healthcare provider or pharmacist for information about paroxetine oral suspensionÂ that is written for healthcare professionals.<br/>Â </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">Â <content styleCode="bold">What are the ingredients in </content>
                              <content styleCode="bold">paroxetine oral suspension?</content>
                              <br/>Â Â <br/>Â <content styleCode="bold">Active ingredient:</content> Paroxetine hydrochloride<br/>Â Â <br/>Â <content styleCode="bold">Inactive ingredients:</content>
                              <br/>Â Â <br/>Â <content styleCode="bold">Oral suspension:</content> polacrilin potassium, microcrystalline cellulose, carboxymethyl cellulose sodium, propylene glycol, glycerin, sorbitol, methylparaben, propylparaben, sodium citrate dihydrate, citric acid anhydrous, sodium saccharin, orange flavor (triacetin, propylene glycol, natural and artificial flavor), FD&amp;C Yellow No. 6, simethicone emulsion and purified water.<br/>Â Â <br/>Â All trademarks are the property of their respective owners.<br/>Â Â <br/>Â Manufactured by:<br/>Â <content styleCode="bold">Novitium Pharma LLC</content>
                              <br/>Â 70 Lake Drive, East Windsor<br/>Â New Jersey 08520Â <br/>Â <br/>For more information about paroxetine oral suspension, call 1-855-204-1431.<br/>Â </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Issued:</content>Â 03/2025</paragraph>
                  <paragraph>LB4256-06</paragraph>
               </text>
               <effectiveTime value="20250313"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>med-guide-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="med-guide-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>med-guide-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="med-guide-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>med-guide-3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="med-guide-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>med-guide-4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="med-guide-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>med-guide-5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="med-guide-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="8e1452d1-02a6-4b48-b86a-fd0f66477678"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <br/>
                  <renderMultiMedia referencedObject="MM16"/>
               </text>
               <effectiveTime value="20250313"/>
               <component>
                  <observationMedia ID="MM16">
                     <text>paroxetine</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="paroxetine-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>